Abstract:Macrophages are important effector cells in inflammatory responses. They are involved in bacterial infections and autoimmune diseases but also in the low grade inflammation associated with obesity and metabolic syndrome. Macrophages also have homeostatic functions and they activate healing process associated with inflammation and tissue injury [1-3]. To achieve these multiform tasks, macrophages are programmed to display distinct phenotypes in response to environmental signals [2-5]. For example, Th1 cytokine interferon γ (IFNγ) and toll-like receptor 4 (TLR4) ligand lipopolysaccharide (LPS) trigger classical, i.e. type M1, activation of macrophages, which is typical for bacterial infections and autoimmune reactions [6]. On the other hand, Th2 cytokines interleukin (IL) 4 and 13 trigger alternative, i.e. type M2, activation, which is associated with wound healing but also with the aberrant immune responses associated with overactivation of fibroblasts and subsequent fibrosis [6,7]. Classical activation of macrophages leads to the release of proinflammatory and antimicrobial factors including IL-6, IL-12, tumour necrosis factor (TNF) and nitric oxide (NO) produced by inducible nitric oxide synthase (iNOS) pathway. On the other hand, alternatively activated macrophages express factors that have been associated with recognition of extracellular pathogens and/or stimulation of fibroblasts. Some of Abstract: Peroxisome proliferator-activated receptor (PPAR) agonists, fibrates and thiazolidinediones, are commonly used drugs in the treatment of dyslipidemia and diabetes. Their targets, PPARα and PPARγ, have also been shown to have a role in the regulation of inflammatory responses linking metabolism and inflammation. In the present study we investigated the effects of PPAR agonists on macrophage activation. In addition to the proinflammatory classical activation, we also focused on interleukin (IL) 4 and 13 -induced alternative activation which is a significant macrophage phenotype in tissue repairing processes and in fibrosing diseases. PPARα agonists GW7647 and fenofibrate as well as PPARγ agonist GW1929 inhibited lipopolysaccharide-induced classical macrophage activation and production of the characteristic biomarkers of this phenotype, i.e. IL-6 and nitric oxide, in murine J774 macrophages. Remarkably, the PPARα agonists also inhibited IL-4 and IL-13 –induced expression of alternative activation markers arginase-1, fizz1 and mannose receptor 1 whereas the PPARγ agonist GW1929 enhanced their expression in J774 macrophages. The PPARα agonists GW7647 and fenofibrate also attenuated the production of alternative activation markers chemokine (C-C motif) ligand 13 and plateletderived growth factor in human THP-1 macrophages. The present findings show that PPARα and PPARγ agonists differently regulate classical and alternative macrophage phenotypes. Furthermore, PPARα activation was introduced as a novel concept to down-regulate alternative macrophage activation indicating that PPARα agonists have therapeutic potential in conditions associated with Research Article Open Access

Inhibitory Effect of Peroxisome Proliferator Activated Receptor γ Ligands on Secretion of Inflammatory Cytokine and Matrix Metalloproteinase in Macrophages and Foam Cell

Effect of PPARα Ligands on Secretion of Inflammatory Cytokines in Foam Cells

Effect of PPAR Ligands on Extracellular Matrix Metalloproteinase Inducer Expression in Macrophages and Foam Cells

Inhibitory Effect of Ppar on the Expression of Emmprin in Macrophages and Foam Cells

Effect of Atorvastatin on MMP-9 and Tissue Factor Induced by Oxldl in Human Monocytes-Derived Macrophages

Omega-3 Polyunsaturated Fatty Acids Antagonize Macrophage Inflammation Via Activation of Ampk/Sirt1 Pathway

Pgc-1 Alpha Inhibits Oleic Acid Induced Proliferation And Migration Of Rat Vascular Smooth Muscle Cells

Effects of Ligand-Activation of Peroxisome Proliferator Activated Receptors-Γ (Ppar-Γ) on Expression of ACAT-1 with High Concentrations of Insulin and Glucose

Oxldl/β2gpi/anti-Β2gpi Complex Induced Macrophage Differentiation to Foam Cell Involving TLR4/NF-kappa B Signal Transduction Pathway

PGC1α enhances macrophage efferocytosis in ox-LDL-stimulated RAW264.7 cells by regulating the NLRP3/PPARα axis

High Density Lipoprotein Suppresses Lipoprotein Associated Phospholipase A2 in Human Monocytes-Derived Macrophages Through Peroxisome Proliferator-Activated Receptor-Γ Pathway.

Peroxisome proliferator-activated receptor alpha and gamma agonists differently regulate classical and alternative macrophage activation

Suppression of Pro-inflammatory Adhesion Molecules by PPAR-δ in Human Vascular Endothelial Cells

PPAR-gamma Ligands Inhibit the Expression of Inflammatory Cytokines and Attenuate Autoimmune Myocarditis.

Epigallocatechin-3-Gallate Inhibits Matrix Metalloproteinase-9 and Monocyte Chemotactic Protein-1 Expression Through the 67-Κda Laminin Receptor and the TLR4/MAPK/NF-κB Signalling Pathway in Lipopolysaccharide-Induced Macrophages

Inhibition of Emmprin and Mmp-9 Expression by Epigallocatechin-3-Gallate Through 67-Kda Laminin Receptor in Pma-Induced Macrophages

Oxygenized low density lipoprotein down-regulates the TRPV4 protein expression of macrophage through activation of peroxisome proliferator-activated receptor γ

Effects of Porphyromonas Gingivalis Lipopolysaccharide on Apoptotic Genes in Foam Cells

Oxhdl_3 and Oxldl Induce the Expression of IL-1β,IL-6,HLA-DR,and CD86 in THP-1 Monocyte-Derived Macrophages

Pro‑atherogenic activation of A7r5 cells induced by the oxLDL/β2GPI/anti‑β2GPI complex

Diterpenoids inhibit ox-LDL-induced foam cell formation in RAW264.7 cells by promoting ABCA1 mediated cholesterol efflux